183 related articles for article (PubMed ID: 36537885)
1. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study.
Villarroel PG; Padró JG; Marquina G; Jáñez NM; González EE; Antón A; Sánchez MB; Cáceres AR; López-López R; Cornejo RE; García PB; Fabregat RM; Fernández BC; Bermudo CL; Camps C
Future Oncol; 2022 Nov; 18(35):3913-3927. PubMed ID: 36537885
[TBL] [Abstract][Full Text] [Related]
2. Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care.
Rodríguez AT; Viejo MN; Maradey P; Canal-Sotelo J; Mancilla PG; Rivero SG; Casillas IR; Abián MH; Bermudo CL
Future Oncol; 2022 May; 18(14):1717-1731. PubMed ID: 35137627
[TBL] [Abstract][Full Text] [Related]
3. Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study.
Tuca Rodríguez A; Núñez Viejo M; Maradey P; Canal-Sotelo J; Guardia Mancilla P; Gutiérrez Rivero S; Raja Casillas I; Herrera Abián M; López Bermudo C
Support Care Cancer; 2021 Aug; 29(8):4799-4807. PubMed ID: 33533986
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain.
Velázquez Rivera I; Muñoz Garrido JC; García Velasco P; España Ximénez de Enciso I; Velázquez Clavarana L
Adv Ther; 2014 Jan; 31(1):107-17. PubMed ID: 24385406
[TBL] [Abstract][Full Text] [Related]
5. Fentanyl buccal tablets for breakthrough pain in highly tolerant cancer patients: preliminary data on the proportionality between breakthrough pain dose and background dose.
Mercadante S; Ferrera P; Adile C; Casuccio A
J Pain Symptom Manage; 2011 Sep; 42(3):464-9. PubMed ID: 21477977
[TBL] [Abstract][Full Text] [Related]
6. Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain.
Mercadante S; Caraceni A; Masedu F; Scipioni T; Aielli F
Oncologist; 2020 Feb; 25(2):156-160. PubMed ID: 31862860
[TBL] [Abstract][Full Text] [Related]
7. Characteristics and Treatment of Breakthrought Pain (BTcP) in Palliative Care.
Husic S; Imamovic S; Matic S; Sukalo A
Med Arch; 2017 Aug; 71(4):246-250. PubMed ID: 28974843
[TBL] [Abstract][Full Text] [Related]
8. Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control.
Chiang YH; Lien CT; Su WH; Yen TY; Chen YJ; Lai YL; Lim KH; Dai KY; Chung HP; Hung CY; Leu YS
BMC Palliat Care; 2024 Jun; 23(1):150. PubMed ID: 38877477
[TBL] [Abstract][Full Text] [Related]
9. Breakthrough pain in patients with head & neck cancer. A secondary analysis of IOPS MS study.
Mercadante S; Masedu F; Valenti M; Aielli F
Oral Oncol; 2019 Aug; 95():87-90. PubMed ID: 31345399
[TBL] [Abstract][Full Text] [Related]
10. Current management of breakthrough cancer pain according to physicians from pain units in Spain.
Estévez FV; Alarcón MDL; Mayoral V; de Madariaga M; Margarit C; Duran JA; Martín-Arroyo JMT; Carregal A;
Clin Transl Oncol; 2019 Sep; 21(9):1168-1176. PubMed ID: 30783918
[TBL] [Abstract][Full Text] [Related]
11. Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study.
Mercadante S; Adile C; Masedu F; Marchetti P; Costanzi A; Aielli F
Eur J Pain; 2019 Apr; 23(4):719-726. PubMed ID: 30421474
[TBL] [Abstract][Full Text] [Related]
12. Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS.
Masel EK; Landthaler R; Gneist M; Watzke HH
Support Care Cancer; 2018 Feb; 26(2):491-497. PubMed ID: 28849261
[TBL] [Abstract][Full Text] [Related]
13. Fentanyl for breakthrough cancer pain: where are we?
Meriggi F; Zaniboni A
Rev Recent Clin Trials; 2013 Mar; 8(1):42-7. PubMed ID: 23259417
[TBL] [Abstract][Full Text] [Related]
14. Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.
Mercadante S; Gatti A; Porzio G; Lo Presti C; Aielli F; Adile C; Casuccio A
Curr Med Res Opin; 2012 Jun; 28(6):963-8. PubMed ID: 22480130
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study.
Guitart J; Vargas I; De Sanctis V; Ferreras J; Fuentes J; Salazar R; Vázquez JM; Folch J; Moya J; Ribera H; Rodelas F; Tomás A; Arilla M; Coma J; Aberasturi T; Sintes D; Lombán E
Clin Drug Investig; 2013 Sep; 33(9):675-83. PubMed ID: 23881567
[TBL] [Abstract][Full Text] [Related]
16. Fentanyl for the treatment of tumor-related breakthrough pain.
Bornemann-Cimenti H; Wejbora M; Szilagyi IS; Sandner-Kiesling A
Dtsch Arztebl Int; 2013 Apr; 110(16):271-7. PubMed ID: 23671467
[TBL] [Abstract][Full Text] [Related]
17. The use of rapid onset opioids for breakthrough cancer pain: the challenge of its dosing.
Mercadante S
Crit Rev Oncol Hematol; 2011 Dec; 80(3):460-5. PubMed ID: 21215653
[TBL] [Abstract][Full Text] [Related]
18. Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer.
Magnani C; Giannarelli D; Calvieri A; Dardeli A; Eusepi G; Restuccia MR; Mastroianni C; Casale G
Postgrad Med J; 2018 Oct; 94(1116):566-570. PubMed ID: 30317182
[TBL] [Abstract][Full Text] [Related]
19. Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy.
Zucco F; Bonezzi C; Fornasari D
Adv Ther; 2014 Jul; 31(7):657-82. PubMed ID: 25005168
[TBL] [Abstract][Full Text] [Related]
20. Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy.
Ferrero VT; Oset MM; Masferrer JP; Pardo EH; Sorolla EJ; Largo SC;
Clin Transl Oncol; 2019 Dec; 21(12):1707-1711. PubMed ID: 30949931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]